ATE513823T1 - Mischung und verbindungen von mycelien von antrodia camphorata und deren verwendung - Google Patents

Mischung und verbindungen von mycelien von antrodia camphorata und deren verwendung

Info

Publication number
ATE513823T1
ATE513823T1 AT04254939T AT04254939T ATE513823T1 AT E513823 T1 ATE513823 T1 AT E513823T1 AT 04254939 T AT04254939 T AT 04254939T AT 04254939 T AT04254939 T AT 04254939T AT E513823 T1 ATE513823 T1 AT E513823T1
Authority
AT
Austria
Prior art keywords
compound
relates
present
antrodia camphorata
mixture
Prior art date
Application number
AT04254939T
Other languages
English (en)
Inventor
Massao Hattori
Chia-Chin Sheu
Original Assignee
Simpson Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Simpson Biotech Co Ltd filed Critical Simpson Biotech Co Ltd
Application granted granted Critical
Publication of ATE513823T1 publication Critical patent/ATE513823T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04254939T 2004-08-17 2004-08-17 Mischung und verbindungen von mycelien von antrodia camphorata und deren verwendung ATE513823T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04254939A EP1634877B1 (de) 2004-08-17 2004-08-17 Mischung und Verbindungen von Mycelien von Antrodia Camphorata und deren Verwendung

Publications (1)

Publication Number Publication Date
ATE513823T1 true ATE513823T1 (de) 2011-07-15

Family

ID=34930575

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04254939T ATE513823T1 (de) 2004-08-17 2004-08-17 Mischung und verbindungen von mycelien von antrodia camphorata und deren verwendung

Country Status (3)

Country Link
US (4) US7763723B2 (de)
EP (1) EP1634877B1 (de)
AT (1) ATE513823T1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820632B2 (en) 2002-02-14 2010-10-26 City Of Hope Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules
US8648113B2 (en) * 2004-03-08 2014-02-11 Simpson Biotech Co., Ltd. Mixture and compounds from mycelia of Antrodia camphorata and use thereof
US20100324309A1 (en) * 2008-04-09 2010-12-23 Simpson Biotech Co., Ltd. Novel Mixture and Compounds from Mycelia of Antrodia Camphorata and Use Thereof
TWI426916B (zh) * 2006-10-17 2014-02-21 Simpson Biotech Co Ltd 具有護肝功效之樟芝多醣體
WO2008049265A1 (en) * 2006-10-23 2008-05-02 Simpson Biotech Co., Ltd. Compositions for providing hepatoprotective effect
TWI448294B (zh) 2009-03-04 2014-08-11 高雄醫學大學 增強免疫活性之樟芝子實體水萃取物及其製備方法
ES2574606T3 (es) 2009-11-26 2016-06-21 National Taiwan University Una sustancia activa contra el cáncer de Antrodia camphorata, método de preparación de la misma y uso de la misma
US20110150856A1 (en) * 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
WO2011130729A2 (en) 2010-04-16 2011-10-20 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
TWI452032B (zh) * 2011-01-21 2014-09-11 國鼎生物科技股份有限公司 治療腎病之醫藥組成物
TW201231474A (en) * 2011-01-26 2012-08-01 Univ Kaohsiung Medical Triterpenoid composition of Antrodia cinnamomea, preparation and analysis method thereof
US9713605B2 (en) 2011-11-18 2017-07-25 Simpson Biotech Co., Ltd. Ameliorative or preventive effect of Antrodia cinnamomea in arthritis, cartilage destruction, or chondrocyte death
CN102495167A (zh) * 2011-12-09 2012-06-13 劲牌有限公司 枸杞多糖提取物中枸杞多糖的检测方法
TWI425948B (zh) * 2012-01-20 2014-02-11 優生生物科技股份有限公司 Compositions for the inhibition or killing of Porphyromonas gingivalis and their use for the alleviation or treatment of periodontal disease and other diseases
TWI522112B (zh) * 2012-12-11 2016-02-21 財團法人工業技術研究院 疫苗佐劑、疫苗組合物與牛樟芝子實體之多醣體用於製備一疫苗佐劑的用途
US9480723B2 (en) * 2013-05-02 2016-11-01 Kingland Property Corporation, Ltd. Method of preparing an extract of Antrodia cinnamomea having an elevated antcin C and zhankuic C content
AU2014340241B2 (en) 2013-10-21 2018-11-01 Salk Institute For Biological Studies Mutated fibroblast growth factor (FGF) 1 and methods of use
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
TWI611802B (zh) * 2013-10-23 2018-01-21 善笙生物科技股份有限公司 來自牛樟芝菌絲體的化合物及混合物的用途
TW201521752A (zh) * 2013-12-05 2015-06-16 國立臺灣師範大學 牛樟芝於抗肥胖的應用及其方法
WO2016006733A1 (ko) * 2014-07-09 2016-01-14 강원대학교산학협력단 섬유모세포성장인자 유래의 펩타이드 단편을 포함하는 상처 치료 또는 피부 주름형성 억제용 조성물
CN104072631A (zh) * 2014-07-15 2014-10-01 江苏阜丰生物科技有限公司 一种高效提取深层液态发酵生产樟芝菌丝体多糖的方法
PL3240772T3 (pl) 2014-12-30 2021-06-28 ONENESS BIOTECH CO., Ltd Związki z antrodia camphorata, sposoby ich otrzymywania i ich zastosowanie
EP3061767A1 (de) * 2015-02-25 2016-08-31 Infinitec Activos, S.L. Neue dodekapeptide und mikrokapseln, die mit ihnen funktionalisiert sind, mit abzielung auf fibroblasten
AU2016252426A1 (en) * 2015-04-20 2017-11-23 Salk Institute For Biological Studies Fibroblast growth factor (FGF) 1 mutants and methods of use to reduce blood glucose
EP3368059A4 (de) 2015-10-30 2019-03-27 Salk Institute for Biological Studies Behandlung von steroid-induzierter hyperglykämie mit fibroblastenwachstumsfaktor (fgf)-1-analoga
US10385113B2 (en) 2016-03-30 2019-08-20 The Board Of Trustees Of The University Of Arkansas Engineered FGF compositions and methods of use thereof
CN106699918B (zh) * 2017-01-13 2019-01-29 四川大学 野阳合多糖及其制备方法和应用
MX2019013210A (es) * 2017-05-05 2020-07-20 Trefoil Therapeutics Inc Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos.
US11267855B2 (en) 2018-03-16 2022-03-08 The Board Of Trustees Of The University Of Arkansas Engineered FGF1 and FGF2 compositions and methods of use thereof
US11253527B2 (en) 2019-02-25 2022-02-22 Arjil Biotech Holding Company Limited Method and composition for inhibiting virus infection
US11510902B2 (en) 2019-06-12 2022-11-29 Simpson Biotech Co., Ltd. Method for preventing or treating non-alcoholic fatty liver disease by antrodins
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
EP3845555A1 (de) * 2019-12-31 2021-07-07 Algaeprona Inc. Vektor zur herstellung und expression von menschlichem wachstumsfaktor und mit dem vektor transformierte mikroalgen
TW202200175A (zh) * 2020-04-28 2022-01-01 浩峰生物科技股份有限公司 牛樟芝萃取物(Ant-Ex)減少血管收縮素轉換酶2(ACE-2)蛋白質表現
CN119320462B (zh) * 2024-10-29 2025-11-18 中国科学院昆明植物研究所 茶果樟多糖及其提取方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1560464A (en) * 1978-01-09 1980-02-06 Inst Tonkoi Organic Khim Im A Anticonvulsant
US4188398A (en) * 1978-02-06 1980-02-12 Akopian Nina E Method for treating epilepsy
US4868113A (en) * 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
US5223483A (en) * 1987-10-22 1993-06-29 Merck & Co., Inc. Cysteine-modified acidic fibroblast growth factor
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5750365A (en) * 1993-05-28 1998-05-12 The Ohio State University Research Foundation Isolated nucleic acid encoding a newt acidic fibroblast growth factor (AFGF)
EP1210046A4 (de) * 1999-06-22 2007-05-02 Res Dev Foundation Verbesserter wundverband zur verstärkung der wundheilung
ATE415101T1 (de) * 1999-12-29 2008-12-15 Sergei Mikhailovich Zenovich Physiologisch aktive mittel enthaltend vicinale dithioglykole sowie deren verwendung in unterschiedlichen wirtschaftsbereichen
US6767543B2 (en) * 2000-02-17 2004-07-27 Council Of Agriculture, Executive Yuan Process for producing a culture of Antrodia camphorata and product obtained thereby
US6558943B1 (en) * 2000-09-05 2003-05-06 Sun Ten Pharmaceutical Co., Ltd. Method for propagating fungi using solid state fermentation
CN1192098C (zh) * 2000-11-13 2005-03-09 葡萄王企业股份有限公司 樟芝菌丝体生物活性物质其制备法及含其组成物
CN1386545A (zh) * 2001-05-18 2002-12-25 葡萄王企业股份有限公司 樟芝保肝制剂
US6740517B2 (en) * 2001-12-14 2004-05-25 Ming-Huang Lan Incubation method for obtaining solid culture of Zang Zhi, solid culture obtained therefrom, processed products and use thereof
GB0316232D0 (en) * 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
US7109232B2 (en) * 2004-03-08 2006-09-19 Simpson Biotech Co., Ltd. Compounds from Antrodia camphorata having anti-inflammatory and anti-tumor activity

Also Published As

Publication number Publication date
EP1634877B1 (de) 2011-06-22
US20060052337A1 (en) 2006-03-09
US20090048330A1 (en) 2009-02-19
US7763723B2 (en) 2010-07-27
US20060217310A1 (en) 2006-09-28
US7732482B2 (en) 2010-06-08
US20060089402A1 (en) 2006-04-27
EP1634877A1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
ATE513823T1 (de) Mischung und verbindungen von mycelien von antrodia camphorata und deren verwendung
US7230017B2 (en) Dihydropyridinone derivatives
US5973188A (en) Acetic acid derivatives
DE60330407D1 (de) Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
DK0747374T3 (da) Sulfonamidsubstituerede benzopyraner som kaliumkanalaktivatorer
NO20051411L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk bruk derav samt intermediater til fremstilling derav
SG159380A1 (en) Heteroaryl compounds useful as inhibitors of gsk-3
BRPI0605934A2 (pt) processos para a preparação de ( 3r, 4s) - 4 - ( (4-benziloxi ) fenil ) - 1 - ( 4 - fluorofenil ) - 3 - ( (s) - 3 - ( 4 - fluorofenil ) - 3 - hidroxipropil) - 2 - azetidinona, um intermediário para a sìntese da ezetimiba
DE69915004D1 (de) 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
ATE224394T1 (de) Derivate von dc 107
NO20053762L (no) Kondensert furanforbindelse.
EA200200774A1 (ru) Новые соединения, обладающие гиполипидемической, гипохолестеринемической активностью, способ их получения и содержащие их композиции
IL155965A0 (en) Pharmaceutical compositions containing an imidazole-5-carboxyclic acid derivative
MX2007004637A (es) Sintesis asimetrica de derivados de dihidrobenzofurano.
CA2256438C (en) Aromatic amidine derivatives useful as selective thrombin inhibitors
DK1018511T3 (da) Isochromanforbindelser og fremgangsmåde til deres fremstilling
ATE259376T1 (de) Heterozyklische verbindungen, ihre zwischenprodukte und elastase-inhibitoren
NO20002589L (no) Bifenylamidinderivater
Prugh et al. Methyl 3-0-benzyl-2, 4, 6-trideoxy-6-iodo-α-d-erythro-hexopyranoside, a chiral synthon for the synthesis of inhibitors of HMG-CoA reductase
GB0329379D0 (en) Prostaglandin synthesis
WO2004071428A3 (en) 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
DE60235365D1 (de) Verfahren zur herstellung von 7-amino-syn-3,5-dihydroxyheptansäurederivaten und zwischenverbindungen diesesverfahrens und deren herestellung
CA2676424A1 (en) Taxane derivatives and processes for the preparation thereof
FI60705C (fi) Foerfarande foer framstaellning av 1,4-dihydro-2,6-dimetyl-4-(3-nitrofenyl)-3,5-pyridinkarboxylsyraisopropyl-(2-propoxi-etyl)-ester som anvaendes som perifer vasodilatator
DE60028475D1 (de) Stabilisatormischung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties